Marked elevation in plasma trimethylamine-N-oxide (TMAO) in patients with mitochondrial disorders treated with oral l-carnitine

Oral supplementation with l-carnitine is a common therapeutic modality for mitochondrial disorders despite limited evidence of efficacy. Recently, a number of studies have demonstrated that a gut microbiota-dependent metabolite of l-carnitine, trimethylamine oxide (TMAO), is an independent and dose-...

Descripción completa

Detalles Bibliográficos
Autores principales: Vallance, H.D., Koochin, A., Branov, J., Rosen-Heath, A., Bosdet, T., Wang, Z., Hazen, S.L., Horvath, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047224/
https://www.ncbi.nlm.nih.gov/pubmed/30023305
http://dx.doi.org/10.1016/j.ymgmr.2018.04.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047224/
https://www.ncbi.nlm.nih.gov/pubmed/30023305
http://dx.doi.org/10.1016/j.ymgmr.2018.04.005

Ejemplares similares